HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
M A Petri Selected Research
M A Petri Research Topics
Disease
10
Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/2017 - 02/2000
2
Infections
09/2015 - 02/2013
2
Neoplasms (Cancer)
09/2015 - 02/2013
2
Proteinuria
09/2015 - 06/2014
2
Inflammation (Inflammations)
07/2012 - 02/2000
2
Autoimmune Diseases (Autoimmune Disease)
07/2012 - 04/2012
2
Genetic Predisposition to Disease (Genetic Predisposition)
04/2002 - 02/2000
1
Lupus Nephritis
01/2018
1
Fatigue
01/2017
1
Chronic Disease (Chronic Diseases)
01/2017
1
Oral Candidiasis (Thrush)
06/2014
1
Bacterial Infections (Bacterial Infection)
06/2014
1
Candidiasis (Moniliasis)
06/2014
1
Hypersensitivity (Allergy)
02/2013
1
Melanoma (Melanoma, Malignant)
02/2013
1
Skin Neoplasms (Skin Cancer)
02/2013
1
Cardiovascular Diseases (Cardiovascular Disease)
05/2011
1
Atherosclerosis
05/2011
1
Disease Susceptibility (Diathesis)
02/2000
Drug/Important Bio-Agent (IBA)
3
Autoantibodies
IBA
07/2012 - 07/2009
2
Biomarkers (Surrogate Marker)
IBA
01/2018 - 01/2017
2
B-Cell Activating Factor
IBA
01/2017 - 09/2015
2
AMG623 peptibody
IBA
01/2017 - 09/2015
2
Proteins (Proteins, Gene)
FDA Link
09/2015 - 06/2014
1
Estrogens (Estrogen)
FDA Link
01/2017
1
Antinuclear Antibodies
IBA
01/2017
1
DNA (Deoxyribonucleic Acid)
IBA
01/2017
1
Creatine
IBA
09/2015
1
T-Cell Antigen Receptors (T-Cell Receptor)
IBA
03/2015
1
Adrenal Cortex Hormones (Corticosteroids)
IBA
06/2014
1
Anti-Bacterial Agents (Antibiotics)
IBA
06/2014
1
Hydroxychloroquine (Plaquenil)
FDA Link
Generic
06/2014
1
Prednisone (Sone)
FDA Link
Generic
06/2014
1
belimumab
IBA
02/2013
1
Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
IBA
05/2011
1
Atorvastatin (Lipitor)
FDA Link
05/2011
1
Chromatin
IBA
07/2009
1
Osteopontin
IBA
04/2002
1
Type II Tumor Necrosis Factor Receptors
IBA
02/2000
1
Cytokines
IBA
02/2000
1
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
IBA
02/2000
Therapy/Procedure
2
Therapeutics
01/2017 - 06/2000